Table 1' Patient characteristics

1
Table 1. Patient characteristics

• Mean HbA1c 7.8
• 6 received sulphonylureas
• Fasting plasma glucose 10.5?3.7 mmol/L (range
  8-17 mmol/L)
• Fasting plasma insulin 71.4?36.7 pmol/L

2
Table 2. Effects of rHDL infusion in type 2
diabetes patients
Relative to placebo at end of 4-hour infusion
3
Fig. 1. Potential mechanisms for HDL modulation
of plasma glucose
Skeletal muscle ABCA1 CaMKK AMPK
? Insulin
Pancreas

• Plasma
• glucose

HDL
? Insulin
Peripheral tissues
ABCA1 ATP-binding cassette transporter AI AMPK
AMP-activated protein kinase CaMKK
calcium/calmodulin-dependent protein kinase
kinase